# Skeletal Muscle Relaxants, Non-Benzodiazepine

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                  | Generic Name | Quantity | Time (Days) |
| :------------------------- | :----------- | :------: | :---------: |
| Baclofen Tab               |              |          |             |
| Chlorzoxazone 250, 500 MG <sup>QL</sup> |              |          |             |
| Cyclobenzaprine 5, 10 MG <sup>QL</sup>  |              |          |             |
| Dantrolene                 |              |          |             |
| Methocarbamol <sup>QL</sup>             |              |          |             |
| Tizanidine Tab <sup>QL</sup>            |              |          |             |

### Non-Preferred

| Non-Preferred              | Generic Name | Quantity | Time (Days) |
| :------------------------- | :----------- | :------: | :---------: |
| Baclofen Solution          |              |          |             |
| Carisoprodol               |              |          |             |
| Chlorzoxazone 375, 750 MG <sup>QL</sup> |              |          |             |
| Cyclobenzaprine 7.5 MG <sup>QL</sup>      |              |          |             |
| Cyclobenzaprine ER <sup>QL</sup>         |              |          |             |
| Fleqsuvy                   |              |          |             |
| Lyvispah                  |                   |        |         |
| Metaxalone                 |              |          |             |
| Orphenadrine               |              |          |             |
| Tizanidine Cap             |              |          |             |

## Length of Authorizations

365 Days

**All Authorizations**

Must be prescribed in accordance with FDA approved labeling

## Additional Criteria

### Non-Preferred Criteria

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least **30 days** with at least **one preferred** drug
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics, requests must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Baclofen Solution

Additional Baclofen Solution Criteria

-   Must provide documentation of trial with baclofen tablets or justification why a non-solid oral dosage form is indicated

### Carisoprodol (Soma)

Additional Carisoprodol (Soma) Criteria

-   Must provide medical justification that no other muscle relaxant or agent to treat fibromyalgia, or any musculoskeletal condition, would serve the clinical needs of the patient

### Subsequent Authorization

-   Must provide documentation of patientâ€™s clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=47)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=18)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
